SHS Gesellschaft für Beteiligungsmanagement mbH

News

Current news of SHS and our portfolio companies

19. December 2023 - Uncategorised

Moderate growth in medical technology in Germany: Regulatory hurdles slow down innovation

Patent applications in the field of medical technology and healthcare show a significant decline, now for the third year in a row The implementation of the new regulatory requirements (MDR/IVDR) has far-reaching effects on the German healthcare industry and is leading to a negative trend in new product developments The Medical Technology Index, developed by […]

Read more
19. December 2023 - Uncategorised

SHS Capital sells shares in joint protection expert Betterguards Technology GmbH

After a four-year investment period, SHS Capital sells its shares in Betterguards Technology GmbH to Hochpfiffig GmbH Betterguards has developed a platform technology that protects human joints from ligament and tendon injuries Betterguards products are used in orthopaedic technology, occupational safety and also in the field of professional sports Tübingen / 14.12.2023 SHS Capital is […]

Read more
19. December 2023 - Uncategorised

SHS portfolio company ESSERT Robotics wins prestigious FANUC Innovation Award for outstanding achievements

ESSERT Robotics was recently honored with the prestigious FANUC Innovation Award. The award was presented at the Robot Global Partner of the Year event in Tokyo, Japan. The ESSERT MicroFactory, an innovative and flexible production line, was recognized as a pioneering solution for Industry 4.0. The Award is one of the most prestigious awards and […]

Read more
19. December 2023 - Uncategorised

The advantages of Next Generation Sequencing biosafety tests over in vivo tests – The Next Generation Sequencing (NGS) technology used by PathoQuest is included in international guideline for the Biopharmaceutical Industry

We are pleased to announce that the Next Generation Sequencing technology used by our SHS Capital portfolio company PathoQuest for the safety of biologics has been highlighted in the ICHQ5A(R2) guideline adopted in November 2023. This global guideline is an important regulatory standard for the market. It states: “NGS is favoured as a replacement for […]

Read more
18. December 2023 - Uncategorised

Milestone for CoreMedic: Successful first-in-human application of the ChordArt system

We are pleased to announce that our SHS Capital portfolio company CoreMedic has announced the successful first-in-human transcatheter application of its ChordArt Mitral Valve Vision Repair System. The patient, who suffered from severe degenerative mitral regurgitation due to a mitral valve leaflet, was successfully treated with the ChordArt TMVr system as part of CoreMedic’s first-in-human […]

Read more
25. October 2023 - Uncategorised

PathoQuest publishes study on proprietary NGS-based quality control test

Paris-based SHS portfolio company PathoQuest SAS is a leader in the development and delivery of next-generation sequencing (NGS) tests for biopharmaceuticals. PathoQuest recently published a study with Charles River Laboratories International Inc. showing that PathoQuest’s GMP-compliant, NGS-based test demonstrates greater ability to detect viral contamination compared to in vivo tests. The aim of the study […]

Read more
25. October 2023 - Uncategorised

Pharma automation specialist Essert Robotics wins ISPE RAYA Award for its project with Vetter Pharma

The Baden-Württemberg-based robotics company ESSERT GmbH, which has been part of the SHS portfolio since August 2023 and specialises in the development of intelligent automation solutions for a wide range of application areas with a focus on the pharmaceutical, life science and general industry sectors, has won the prestigious ISPE RAYA Award together with Vetter […]

Read more
1
23
...
Next Last